Advantages of T-Cell Immunotherapy Over CAR T-Cells

Video

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.

“[Tab-cel] is actually really advantageous because when [patients] get the therapy, there's no special things people have to do. There's no premedication, you infuse therapy, watch the patients for 2 hours for vital stats, and if they walked in to get their therapy, they walk out and go back home. It's a very different administration profile than some of the other therapies.”

Atara Biotherapeutics is assessing tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the phase 3 ALLELE study (NCT03394365). They are reporting updated data at the upcoming American Society of Hematology 2021 Meeting, December 11-14.

Independent objective response rate was 50% (95% CI [33.4, 66.6]; n = 19) in the ALLELE study, which has enrolled 38 evaluable, heavily pretreated patients with EBV+ PTLD as of May 2021. Median duration of response could not yet be assessed, but 11 patients had a duration of response of at least 6 months. Investigators observed no new safety signals or concerns, and safety findings were consistent with previously published data.

GeneTherapyLive spoke with AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, to learn more about tab-cel and the advantages the therapy offers over other T-cell therapies, including chimeric antigen receptor (CAR) T-cell therapies.

REFERENCE
Atara Biotherapeutics to present eight abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, including first presentation of Tab-cel® pivotal phase 3 (ALLELE) data. News release. Atara Biotherapeutics. November 4, 2021. https://www.businesswire.com/news/home/20211104005811/en/Atara-Biotherapeutics-to-Present-Eight-Abstracts-at-the-63rd-American-Society-of-Hematology-ASH-Annual-Meeting-Including-First-Presentation-of-Tab-cel%C2%AE-Pivotal-Phase-3-ALLELE-Data

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.